We are international
Donate
• about myeloma TEXT SIZE   
the understanding series    back

Myeloma Minute - Special Edition:
FDA Grants 'Priority Review' for Revlimid
03.03.06
MYELOMA MINUTE:
SPECIAL EDITION:
FDA GRANTS "PRIORITY REVIEW"
FOR REVLIMID®
IN COMBINATION WITH DEX
FOR RELAPSED/REFRACTORY MM

The IMF is dedicated to improving the quality of life of myeloma patients
while working toward prevention and a cure.

Revlimid could be approved for multiple myeloma no later than the end of June.

Celgene, which makes Revlimid, says the FDA has granted a "priority review" for Revlimid in combination with dexamethasone for myeloma patients who have been treated with at least one previous regimen.

Priority review advances an approval date, and is granted when the FDA believes a drug could be a "significant improvement compared to existing products or approved therapies."

Revlimid has been approved for use with a blood disorder called MDS. Approval of Revlimid for myeloma would make it available to a wider range of patients and would help resolve some of the current pricing issues for myeloma patients. During the review period, Celgene says Revlimid will remain available free of charge to patients who qualify for the Expanded Access Program, or who can enter clinical trials. The IMF Hotline at (800) 452-CURE can assist patients with information about these and other support programs, and about the RevAssist program that allows Revlimid to be distributed only by specific contract pharmacies.

YOU ALSO MIGHT BE INTERESTED IN:


 related articles